Berlex Launches Newly Designed Web Site for Multiple Sclerosis
Berlex, Inc., a U.S. affiliate of Schering AG, Germany (NYSE: SHR; FSE: SCH) and marketers of Betaseron(R) (interferon beta-1b), today announced the launch of Betaseron.com, its redesigned Web site for people ...
Mwc.com | Oct 11, 2004
Multiple Sclerosis No Obstacle for Cross-Country Cyclist With a Mission
With the support of his family and sponsorship from Berlex, Inc., Richardson used his journey to encourage people with MS across the country, sharing his belief that those living with the disease can lead full ...
WNEM Saginaw | Sep 27, 2004
Study shows Copaxone may be more effective than interferon-beta...
Teva Pharmaceutical Industries Ltd. s Copaxone (glatiramer acetate injection) may be more effective than interferon-beta therapy in reducing fatigue in multiple sclerosis patients, suggest findings from a new study.
Biopharm | Jul 2, 2004
Long-Term Follow-Up Studies Underscore Proven Benefits of Betaseron(R) Treatment
Berlex Inc., a U.S. affiliate of Schering AG, Germany , announced today that the proven benefits of interferon beta-1b (Betaseron(R)) treatment for people living with multiple sclerosis (MS) was underscored by ...
Mwc.com | Oct 11, 2004
Hemispherx Launches MS Salvage Program with Natural Interferons
All recombinant beta interferon products have been reported to induce neutralizing antibodies (NAB) in a proportion of the patients that may compromise therapeutic efficacy and long ...
Bio.com | Jun 15, 2004
MS Study Shows Higher Beta Interferon Dose Improves MRI Outcomes
Increasing the dose of Betaferon(r) (interferon beta-1b) significantly improves the response of multiple sclerosis (MS) patients who exhibit persisting signs of disease activity with ...
Med Ad News | Apr 28, 2004
